MOSAIC Mobile Program for Type 2 Diabetes
(MOSAIC Trial)
Trial Summary
What is the purpose of this trial?
This behavioral clinical trial evaluates an adaptively tailored, mobile phone-delivered intervention (MOSAIC) designed to support adults managing their type 2 diabetes. Adaptive means the intervention can change over time. Tailored means the intervention may be different for different participants. The main questions the study will aim to answer are: 1. Does the diabetes education and support delivered via the MOSAIC adaptive mobile phone-delivered intervention improve outcomes more than diabetes education and support delivered via print materials alone? This aim compares the study arms on outcomes such as glycemic management (hemoglobin A1c), diabetes distress, and psychosocial well-being. This aim also compares the study arms on intervention targets (mediators) including diabetes self-efficacy and self-care behaviors. 2. For whom does the MOSAIC adaptive tailoring approach improve outcomes more than the print materials alone? This aim examines how well the tailoring rules used for the MOSAIC intervention worked for different participants on the outcomes examined in the first aim. Participants will enroll in a 16-month study with assessments every 4 months. Assessments include completion of an A1c test and a survey. For those assigned to MOSAIC, they will experience 12-months of mobile phone-delivered support with 3 opportunities for intervention tailoring.
Research Team
Eligibility Criteria
This trial is for adults with type 2 diabetes who are interested in managing their condition. Participants will be involved in a 16-month study, but specific inclusion and exclusion criteria details are not provided.Inclusion Criteria
Exclusion Criteria
Treatment Details
Interventions
- MOSAIC (Behavioural Intervention)
Find a Clinic Near You
Who Is Running the Clinical Trial?
Vanderbilt University Medical Center
Lead Sponsor
Jeffrey R. Balser
Vanderbilt University Medical Center
Chief Executive Officer since 2009
MD and PhD from Vanderbilt University
Rick W. Wright
Vanderbilt University Medical Center
Chief Medical Officer since 2023
MD from University of Missouri-Columbia
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Collaborator
Dr. Griffin P. Rodgers
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Chief Executive Officer since 2007
MD, M.A.C.P.
Dr. Griffin P. Rodgers
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Chief Medical Officer since 2007
MD, M.A.C.P.
University of Alabama at Birmingham
Collaborator
Kierstin Kennedy
University of Alabama at Birmingham
Chief Medical Officer since 2022
MD
S. Dawn Bulgarella
University of Alabama at Birmingham
Chief Executive Officer since 2023
BSc in Commerce and Business Administration from the University of Alabama, MS in Health Administration from the University of Alabama at Birmingham